Table 3. Results of multivariate Cox proportional hazards regression analysis performed to assess the impact of multiple factors on overall survival (OS) from first phase I treatment.
| Variable | Contrast | Hazard ratio (95% CI) | P value |
|---|---|---|---|
| ECOG performance status | > 0 vs. 0 | 1.47 (0.90, 2.41) | 0.12 |
| Liver metastases | Yes vs. No | 1.72 (1.01, 2.91) | 0.045 |
| No. of metastatic sites | >2 vs. <= 2 | 1.33 (0.9, 2.25) | 0.28 |
| Prior radiation therapy | Yes vs. No | 1.58 (0.95, 2.61) | 0.077 |
| Prior FOLFIRINOX | Yes vs. No | 1.73 (1.01, 2.98) | 0.046 |
| Prior gemcitabine plus nab-paclitaxel treatment | Yes vs. No | 1.08 (0.58, 2.01) | 0.80 |
FOLFIRINOX, 5-fluorouracil, oxaliplatin, and irinotecan.